An Open-Label Phase I, Multi-Center Study to Determine the Recommended Dose of the Chimeric Antigen Receptor T-cell Treatment CYAD-211 After a Non-Myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients with Relapsed or Refractory Disease (IMMUNICY-1)
This study aims to determine the recommended dose of the allogeneic CYAD-211 (anti-BCMA CAR-T) cells after a non-myeloablative preconditioning chemotherapy in multiple myeloma (MM) patients with relapsed or refractory disease.
The primary objective of this Phase I study is to determine the recommended dose (RecD) for the CYAD-211 investigational product when administered as a single infusion after a non-myeloablative preconditioning chemotherapy in MM patients with relapsed or refractory disease.
The secondary objectives of this Phase I study are:
-Evaluation of additional safety parameters
-Evaluation of indicators of clinical activity
Exploratory objectives of this Phase I study are:
-Kinetics of CYAD-211 in peripheral blood, bone marrow and extramedullary tumor sites/plasmacytoma
-Systemic cytokine and chemokine kinetics
-BCMA and other immune targets expression on normal cells and tumor cells in bone marrow, extramedullary tumor sites/plasmacytoma, and peripheral blood
-soluble BCMA and other immune targets kinetics
-evolution of the clonality of tumor cells in bone marrow samples or aspirate
-Degree of HLA mismatching between each patient treated and CYAD-211
-Phenotype of CYAD-211 T-cells post-infusion and relative frequency of T-cell subsets
-Patient's immune response against CYAD-211
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub